Multaq Related Published Studies
Well-designed clinical trials related to Multaq (Dronedarone)
Estimation of potential cost savings associated with reduced rates of
cardiovascular hospitalization among atrial fibrillation/flutter patients treated
with dronedarone in the ATHENA trial. [2014]
Effects of dronedarone started rapidly after amiodarone discontinuation. [2013]
Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). [2011.04.01]
Impact of dronedarone on hospitalization burden in patients with atrial
fibrillation: results from the ATHENA study. [2011]
Effect of dronedarone on exercise capacity and cardiac function in patients with severe left ventricular dysfunction and compensated stable heart failure. [2010.12]
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. [2010.12]
Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials. [2010.05.14]
Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. [2009.09.29]
Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. [2009.09.15]
Effect of dronedarone on cardiovascular events in atrial fibrillation. [2009.02.12]
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. [2008.09]
Increased mortality after dronedarone therapy for severe heart failure. [2008.06.19]
Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter. [2008.01]
Effect of dronedarone on renal function in healthy subjects. [2007.12]
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. [2007.09.06]
Well-designed clinical trials possibly related to Multaq (Dronedarone)
New approaches to atrial fibrillation management: treat the patient, not the ECG. [2010.10]
New Approaches to Atrial Fibrillation Management: Treat the Patient, not the ECG. [2010.03.25]
Other research related to Multaq (Dronedarone)
The role of dronedarone in the treatment of atrial fibrillation/flutter in the
aftermath of PALLAS. [2014]
Dronedarone for the Treatment of Atrial Fibrillation: A NICE Single Technology Appraisal. [2011.12.02]
Dronedarone and the Incidence of Stroke in Patients with Paroxysmal or Persistent Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Trials. [2011.10.31]
Impact of dronedarone on hospitalization burden in patients with atrial fibrillation: results from the ATHENA study. [2011.08]
Dronedarone for atrial fibrillation therapy. [2011.06]
Effect of dronedarone on Na+, Ca2+ and HCN channels. [2011.04]
Dronedarone for the management of atrial fibrillation. [2011.03.02]
[Perspectives and recommendations for the anti-arrhythmic treatment of atrial fibrillation: focus on dronedarone]. [2011.03]
Dronedarone for atrial fibrillation: How does it compare with amiodarone? [2011.03]
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. [2011.03]
Dronedarone. [2011.02]
Dronedarone: current evidence for its safety and efficacy in the management of atrial fibrillation. [2011.01.06]
[The role of dronedarone in the contemporary atrial fibrillation treatment]. [2011.01]
Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. [2011.01]
Effects of dronedarone on clinical outcomes in patients with lone atrial
fibrillation: pooled post hoc analysis from the ATHENA/EURIDIS/ADONIS studies. [2011]
Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and
propafenone, for the management of atrial fibrillation. [2011]
A review of the appropriate and inappropriate use of dronedarone: lessons learned from controlled studies and regulatory submission. [2010.12]
[Dronedarone]. [2010.12]
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. [2010.10.05]
Dronedarone for the treatment of atrial fibrillation and atrial flutter. [2010.10]
Dronedarone and vitamin K antagonists: a review of drug-drug interactions. [2010.10]
Dronedarone: a new antiarrhythmic agent. [2010.09]
Worsening heart failure in the setting of dronedarone initiation. [2010.09]
Effect of Dronedarone on Exercise Capacity and Cardiac Function in Patients With Severe Left Ventricular Dysfunction and Compensated Stable Heart Failure. [2010.07.21]
Dronedarone in patients with congestive heart failure: insights from ATHENA. [2010.07]
A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. [2010.06.01]
Dronedarone: a review of characteristics and clinical data. [2010.06]
Dronedarone: an emerging therapy for atrial fibrillation. [2010.06]
Dronedarone for atrial fibrillation have we expanded the antiarrhythmic armamentarium? [2010.04.13]
Impact of dronedarone in atrial fibrillation and flutter on stroke reduction. [2010.04.07]
[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?] [2010.03]
[Clinical pharmacology and electrophysiological properties of dronedarone] [2010.03]
[Clinical profile of the new antiarrhythmic drug dronedarone] [2010.03]
Dronedarone: current evidence and future questions. [2010.03]
Dronedarone--a new alternative for management of atrial fibrillation. [2010.01.01]
Efficacy and safety of dronedarone: a review of randomized trials. [2010.01]
Dronedarone: a novel antiarrhythmic agent for the treatment of atrial fibrillation. [2010.01]
Dronedarone for the treatment of atrial fibrillation and atrial flutter. [2010]
Dronedarone in patients with congestive heart failure: insights from ATHENA. [2010]
Dronedarone: a novel antiarrhythmic agent for the treatment of atrial
fibrillation. [2010]
Dronedarone: a promising alternative for the management of atrial fibrillation. [2009.10]
Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation. [2009.09]
Estradiol valerate/dienogest: in oral contraception. [2009.08.20]
Dronedarone. [2009.08.18]
[Dronedarone: the new antiarrythmic agent?] [2009.06]
Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone. [2009.05]
Dronedarone for atrial fibrillation: a new therapeutic agent. [2009]
Other possibly related research studies
Prevention of stroke in patients with atrial fibrillation: the role of new antiarrhythmic and antithrombotic drugs. [2010.08]
Cost burden of cardiovascular hospitalization and mortality in ATHENA-like patients with atrial fibrillation/atrial flutter in the United States. [2010.05]
Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention. [2010.05]
New and emerging antiarrhythmic and anticoagulant agents for atrial fibrillation. [2010.05.01]
New antiarrhythmic drugs for treatment of atrial fibrillation. [2010.04.03]
[Current antiarrhythmic drug therapy in atrial fibrillation] [2010.03]
Recent advances in the pharmacological treatment of cardiac arrythmias. [2009.11]
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? [2010.02]
Amiodarone and thyroid. [2009.12]
Effects of amiodarone therapy on thyroid function. [2010.01]
Cardioversion of atrial fibrillation: the use of antiarrhythmic drugs. [2010.03]
New and emerging antiarrhythmic drugs for atrial fibrillation: what may become available to the clinician in the near future. [2009.10]
Atrial Ca2+ signaling in atrial fibrillation as an antiarrhythmic drug target. [2010.03]
Pharmacologic management of atrial fibrillation: established and emerging options. [2009.08]
[Treatment of atrial fibrillation in heart failure] [2009.03]
Novel approaches for pharmacological management of atrial fibrillation. [2009]
Major recent trials in cardiovascular diseases. [2009.03]
Pharmacotherapy for atrial arrhythmias: present and future. [2008.06]
Mixed learning algorithms and features ensemble in hepatotoxicity prediction. [2011.09]
Is antiarrhythmic treatment in the elderly different?: a review of the specific changes. [2011.08.01]
Atrial fibrillation: epidemiology, prognosis and therapy. [2011.06]
Delayed and indirect effects of antiarrhythmic drugs in reducing sudden cardiac death. [2011.03]
[Treatment of atrial fibrillation: when to use drugs or to perform ablation]. [2010.10]
Antiarrhythmic drugs management in patients with atrial fibrillation: the new guidelines. [2011.04]
Treating arrhythmias: an expert opinion. [2011.06]
Post-ATHENA and beyond. [2011.06]
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. [2011.01]
Antiarrhythmic drugs for atrial fibrillation. [2011.06]
Electrophysiology and adult congenital heart disease: advances and options. [2011.01]
[Epidemiology, clinical picture and management of atrial fibrillation]. [2011.02]
Sinus rhythm restoration and treatment success: insight from recent clinical trials. [2011.01]
[Current management of atrial fibrillation: rhythm or rate control and thoughts about a new treatment paradigm]. [2010.12]
[Management of atrial fibrillation, what to know on old and new antiarrhythmics]. [2010.12]
The pharmaceutical pipeline for atrial fibrillation. [2011.02]
Advances in the treatment of atrial fibrillation. [2010.12]
Augmenting maintenance of sinus rhythm in the control of atrial fibrillation by antiarrhythmic drug combinations. [2010.12]
[New developments in the antiarrhythmic therapy of atrial fibrillation]. [2010.12]
|